Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 10/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.55 |
| ▸ | GSK3B | P49841 | 8/20 | 0.55 |
| ▸ | AKT1 | P31749 | 7/20 | 0.55 |
| ▸ | AKT2 | P31751 | 7/20 | 0.55 |
| ▸ | AKT3 | Q9Y243 | 5/20 | 0.55 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14008040 | 0.85 | AKT1 (0.62) | RPS6KA5ROCK1GSK3BAKT1AKT2 | |
| SCHEMBL3997256 | 0.82 | ROCK1 (0.77) | RPS6KA5ROCK1GSK3BPRKACARPS6KB1 | |
| SCHEMBL5069106 | 0.82 | AKT1 (0.80) | GSK3BAKT1AKT2AKT3 | |
| SCHEMBL4594546 | 0.80 | AKT1 (0.57) | RPS6KA5ROCK1GSK3BAKT1AKT2 | |
| SCHEMBL4596295 | 0.79 | AKT1 (0.55) | RPS6KA5ROCK1GSK3BAKT1AKT2 | |
| SCHEMBL4595536 | 0.79 | RPS6KA5 (0.69) | RPS6KA5ROCK1GSK3BAKT1AKT2 | |
| SCHEMBL13997822 | 0.78 | AKT1 (0.52) | RPS6KA5ROCK1GSK3BAKT1AKT2 | |
| SCHEMBL4606693 | 0.78 | RPS6KA5 (0.52) | RPS6KA5ROCK1GSK3BAKT1AKT2 | |
| SCHEMBL4595603 | 0.77 | RPS6KA5 (0.66) | RPS6KA5ROCK1GSK3BAKT1AKT2 | |
| SCHEMBL13997805 | 0.77 | RPS6KA5 (0.66) | RPS6KA5ROCK1GSK3BAKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | RPS6KA5 156/4885ROCK1 478/4885GSK3B 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.